Septomics: Application of systems approaches to sepsis - potential for personalized management of septic patients

Current Pharmacogenomics and Personalized Medicine

Volumn 8, Issue 2, 2010, Pages 97-107

  Kotb, Malak ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Complex trait diseases; Gene environment interactions; Physiome; Sepsis; Septomics; Systems biology; Systems genetics; Translational medicine and personalized patient care

Indexed keywords

ARTICLE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GENE TECHNOLOGY; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; INFECTION SENSITIVITY; SEPSIS; SYSTEMS BIOLOGY;

EID: 77953796395     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569210791383910     Document Type: Article

References (169)

1. Voit EO. A systems-theoretical framework for health and disease: inflammation and preconditioning from an abstract modeling point of view. Math Biosci 2009; 217: 11-8.
2. Hood L, Heath JR, Phelps ME, et al. Systems biology and new technologies enable predictive and preventative medicine. Science 2004; 306: 640-3.
3. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 2004; 3: 179-96.
4. Voit EO, Brigham K. The role of systems biology in predictive health and personalized medicine. Open Pathol J 2008; 2: 68-70.
5. Sutherland AM, Walley KR. Bench-to-bedside review: Association of genetic variation with sepsis. Crit Care 2009; 13: 210.
6. Funk D, Sebat F, Kumar A. A systems approach to the early recognition and rapid administration of best practice therapy in sepsis and septic shock. Curr Opin Crit Care 2009; 15: 301-7.
7. Kellam P, Holzerlandt R, Gramoustianou E, et al. Viral bioinformatics: computational views of host and pathogen. Novartis Found Symp 2003; 254: 234-47.
8. Bao L, Peirce JL, Zhou M, et al. An integrative genomics strategy for systematic characterization of genetic loci modulating phenotypes. Hum Mol Genet 2007; 16: 1381-90.
9. Carlborg O, De Koning DJ, Manly KF, et al. Methodological aspects of the genetic dissection of gene expression. Bioinformatics 2005; 21: 2383-93.
10. Vernon SD, Reeves WC. The challenge of integrating disparate high-content data: epidemiological, clinical and laboratory data collected during an in-hospital study of chronic fatigue syndrome. Pharmacogenomics 2006; 7: 345-54.
11. Wenk MR. The emerging field of lipidomics. Nat Rev Drug Discov 2005; 4: 594-610.
12. Auffray C, Imbeaud S, Roux-Rouquie M, et al. From functional genomics to systems biology: concepts and practices. CR Biol 2003; 326: 879-92.
13. Kell DB. Metabolomics and systems biology: making sense of the soup. Curr Opin Microbiol 2004; 7: 296-307.
14. Kotb M. Genetics of susceptibility to infectious diseases. ASM News 2004; 70(10): 457-63.
15. Kotb M, Fathey N, Aziz R, et al. Unbiased forward genetics and systems biology approaches to understanding how geneenvironment interactions work to predict susceptibility and outcomes of infections. Novartis Found Symp 2008; 293: 156-65.
16. Andreasen CH, Andersen G. Gene-environment interactions and obesity--further aspects of genomewide association studies. Nutrition 2009; 25: 998-1003.
17. Plomin R, Haworth CM, Davis OS. Common disorders are quantitative traits. Nat Rev Genet 2009; 10: 872-8.
18. Abiola O, Angel JM, Avner P, et al. The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet 2003; 4: 911-6.
19. Skelly DA, Ronald J, Akey JM. Inherited variation in gene expression. Annu Rev Genomics Hum Genet 2009; 10: 313-32.
20. Frazer KA, Murray SS, Schork NJ, et al. Human genetic variation and its contribution to complex traits. Nat Rev Genet 2009; 10: 241-51.
21. Ozdemir V, Husereau D, Hyland S, et al. Personalized medicine beyond genomics: new technologies, global health diplomacy and anticipatory governance. Curr Pharmacogenomics Person Med 2009; 7 (4): 225-30.
22. Van de Vijver G. No genetics without epigenetics? No biology without systems biology? Ann NY Acad Sci 2009; 1178: 305-17.
23. Moerer O, Quintel M. [Sepsis in adult patients definitions, epidemiology and economic aspects]. Internist (Berl) 2009; 50: 788, 790-4, 796-8.
24. Annane D. Improving clinical trials in the critically ill: unique challenge-sepsis. Crit Care Med 2009; 37: S117-28.
25. Opal SM, Cross AS. Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 1999; 13: 285-97.
26. Marshall JC, Reinhart K. Biomarkers of sepsis. Crit Care Med 2009; 37: 2290-8.
27. Shapiro NI, Trzeciak S, Hollander JE, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 2009; 37: 96-104.
28. Sebastiani P, Timofeev N, Dworkis DA, et al. Genome-wide association studies and the genetic dissection of complex traits. Am J Hematol 2009; 84: 504-15.
29. Manolio TA. Collaborative genome-wide association studies of diverse diseases: programs of the NHGRI's office of population genomics. Pharmacogenomics 2009; 10: 235-41.
30. Panoutsopoulou K, Zeggini E. Finding common susceptibility variants for complex disease: past, present and future. Brief Funct Genomic Proteomic 2009; 8: 345-52.
31. Cookson W, Liang L, Abecasis G, et al. Mapping complex disease traits with global gene expression. Nat Rev Genet 2009; 10: 184-94.
32. Ryten M, Trabzuni D, Hardy J. Genotypic analysis of gene expression in the dissection of the aetiology of complex neurological and psychiatric diseases. Brief Funct Genomic Proteomic 2009; 8: 194-8.
33. Aylor DL, Zeng ZB. From classical genetics to quantitative genetics to systems biology: modeling epistasis. PLoS Genet 2008; 4: e1000029.
34. Cheng JC, Moore TB, Sakamoto KM. RNA interference and human disease. Mol Genet Metab 2003; 80: 121-8.
35. Lopez-Fraga M, Martinez T, Jimenez A. RNA interference technologies and therapeutics: from basic research to products. BioDrugs 2009; 23: 305-32.
36. Prudêncio M, Lehmann M. Illuminating the host how RNAi screens shed light on host-pathogen interactions. Biotechnol J 2009; 4: 826-37.
37. Zhang R, Su B. Small but influential: the role of microRNAs on gene regulatory network and 3'UTR evolution. J Genet Genomics 2009; 36: 1-6.
38. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
39. Marson A, Levine SS, Cole MF, et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008; 134: 521-33.
40. Jungblut PR, Zimny-Arndt U, Zeindl-Eberhart E, et al. Proteomics in human disease: cancer, heart and infectious diseases. Electrophoresis 1999; 20: 2100-10.
41. McGarvey PB, Huang H, Mazumder R, et al. Systems integration of biodefense omics data for analysis of pathogen-host interactions and identification of potential targets. PLoS One 2009; 4: e7162.
42. Robalino J, Carnegie RB, O'Leary N, et al. Contributions of functional genomics and proteomics to the study of immune responses in the Pacific white leg shrimp Litopenaeus vannamei. Vet Immunol Immunopathol 2009; 128: 110-8.
43. Sheeley DM, Breen JJ, Old SE. Building integrated approaches for the proteomics of complex, dynamic systems: NIH programs in technology and infrastructure development. J Proteome Res 2005; 4: 1114-22.
44. Khan AS, Mujer CV, Alefantis TG, et al. Proteomics and bioinformatics strategies to design countermeasures against infectious threat agents. J Chem Inf Model 2006; 46: 111-5.
45. Huang S, Triche T, Jong A. Infectomics: genomics and proteomics of microbial infections. Funct Integr Genomics. 2002; 1: 331-44.
46. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009; 37: 291-304.
47. Almasy L, Blangero J. Human QTL linkage mapping. Genetica 2009; 136: 333-40.
48. Williams RW. Expression genetics and the phenotype revolution. Mamm Genome 2006; 17: 496-502.
49. Dixon SJ, Costanzo M, Baryshnikova A, et al. Systematic mapping of genetic interaction networks. Annu Rev Genet 2009; 43: 601-25.
50. Voit EO, Qi Z, Miller GW. Steps of modeling complex biological systems. Pharmacopsychiatry 2008; 41(Suppl 1): S78-84.
51. Pomp D, Allan MF, Wesolowski SR. Quantitative genomics: exploring the genetic architecture of complex trait predisposition. J Anim Sci 2004; 82(E-Suppl): E300-312.
52. Dyson A, Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 2009; 37: S30-7.
53. Balling R. From mouse genetics to systems biology. Mamm Genome 2007; 18: 383-8.
54. Arcaroli J, Fessler MB, Abraham E. Genetic polymorphisms and sepsis. Shock 2005; 24: 300-12.
55. Brunkhorst FM, Reinhart K. [Diagnosis and causal treatment of sepsis]. Internist (Berl) 2009; 50: 810-6.
56. Brazier JE, Dixon S, Ratcliffe J. The role of patient preferences in cost-effectiveness analysis: a conflict of values? Pharmacoeconomics 2009; 27: 705-12.
57. Morrell MR, Micek ST, Kollef MH. The management of severe sepsis and septic shock. Infect Dis Clin North Am 2009; 23: 485-501.
58. Dahmer MK, Randolph A, Vitali S, et al. Genetic polymorphisms in sepsis. Pediatr Crit Care Med 2005; 6: S61-73.
59. Wheeler DS, Zingarelli B, Wheeler WJ, et al. Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov 2009; 3: 96-112.
60. Ulloa L, Brunner M, Ramos L, et al. Scientific and clinical challenges in sepsis. Curr Pharm Des 2009; 15: 1918-35.
61. Robson WP, Daniel R. The Sepsis Six: helping patients to survive sepsis. Br J Nurs 2008; 17: 16-21.
62. Sogayar AM, Machado FR, Rea-Neto A, et al. A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics 2008; 26: 425-34.
63. Jacobson S, Johansson G, Winso O. Primary sepsis in a university hospital in northern Sweden: a retrospective study. Acta Anaesthesiol Scand 2004; 48: 960-7.
64. Edbrooke D, Hibbert C, Kingsley J, et al. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 1999; 27: 1760-7.
65. Carlet J, Cohen J, Calandra T, et al. Sepsis: time to reconsider the concept. Crit Care Med 2008; 36: 964-6.
66. Carpenter CR, Keim SM, Upadhye S, et al. Risk stratification of the potentially septic patient in the emergency department: the Mortality in the Emergency Department Sepsis (MEDS) score. J Emerg Med 2009; 37: 319-27.
67. Opal SM. Concept of PIRO as a new conceptual framework to understand sepsis. Pediatr Crit Care Med 2005; 6: S55-60.
68. Rooney Z, Nadel S. Optimizing intensive care management in paediatric sepsis. Curr Opin Infect Dis 2009; 22: 264-71.
69. Trejnowska E, Popovich MJ. Management of sepsis in the ICU. Int Anesthesiol Clin 2009; 47: 55-66.
70. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8: 32-43.
71. Abraham E, Matthay MA, Dinarello CA, et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med 2000; 28: 232-5.
72. Melamed A, Sorvillo FJ. The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiplecause-of-death data. Crit Care 2009; 13: R28.
73. Kotb M, Norrby-Teglund A, McGeer A, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002; 8: 1398-404.
74. Kotb M, Norrby-Teglund A, McGeer A, et al. Association of human leukocyte antigen with outcomes of infectious diseases: the streptococcal experience. Scand J Infect Dis 2003; 35: 665-9.
75. Opal SM. Severe sepsis and septic shock: defining the clinical problem. Scand J Infect Dis 2003; 35: 529-34.
76. Marshall J. Sepsis: rethinking the approach to clinical research. J Leukoc Biol 2008; 83: 471-82.
77. Houston G, Cuthbertson BH. Activated protein C for the treatment of severe sepsis. Clin Microbiol Infect 2009; 15: 319-24.
78. Threadgill DW, Hunter KW, Williams RW. Genetic dissection of complex and quantitative traits: from fantasy to reality via a community effort. Mamm Genome 2002; 13: 175-8.
79. Buhimschi CS, Bhandari V, Han YW, et al. Using proteomics in perinatal and neonatal sepsis: hopes and challenges for the future. Curr Opin Infect Dis 2009; 22: 235-43.
80. Belknap JK, Hitzemann R, Crabbe JC, et al. QTL analysis and genomewide mutagenesis in mice: complementary genetic approaches to the dissection of complex traits. Behav Genet 2001; 31: 5-15.
81. Hitzemann R, Malmanger B, Reed C, et al. A strategy for the integration of QTL, gene expression, and sequence analyses. Mamm Genome 2003; 14: 733-47.
82. Churchill GA, Airey DC, Allayee H, et al. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet 2004; 36: 1133-7.
83. Chesler EJ, Lu L, Shou S, et al. Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modu late nervous system function. Nat Genet 2005; 37: 233-42.
84. Wang J, Williams RW, Manly KF. WebQTL: web-based complex trait analysis. Neuroinformatics 2003; 1: 299-308.
85. Williams RW, Gu J, Qi S, et al. The genetic structure of recombi nant inbred mice: high-resolution consensus maps for complex trait analysis. Genome Biol 2001; 2: RESEARCH0046.
86. Zou F, Gelfond JA, Airey DC, et al. Quantitative trait locus analysis using recombinant inbred intercrosses: theoretical and empirical considerations. Genetics 2005; 170: 1299-311.
87. Rosen GD, Chesler EJ, Manly KF, et al. An informatics approach to systems neurogenetics. Methods Mol Biol 2007; 401: 287-303.
88. Goel G, Chou IC, Voit EO. System estimation from metabolic time-series data. Bioinformatics 2008; 24: 2505-11.
89. Aziz RK, Kansal R, Abdeltawab NF, et al. Susceptibility to severe Streptococcal sepsis: use of a large set of isogenic mouse lines to study genetic and environmental factors. Genes Immun 2007; 8: 404-15.
90. Yang J, Zhu J, Williams RW. Mapping the genetic architecture of complex traits in experimental populations. Bioinformatics 2007; 23: 1527-36.
91. Gatti D, Maki A, Chesler EJ, et al. Genome-level analysis of genetic regulation of liver gene expression networks. Hepatology 2007; 46: 548-57.
92. Dixon SJ, Stockwell BR. Identifying druggable disease-modifying gene products. Curr Opin Chem Biol 2009; 13: 549-55.
93. Peng X, Chan EY, Li Y, et al. Virus-host interactions: from systems biology to translational research. Curr Opin Microbiol 2009; 12: 432-8.
94. Voit EO. Modelling metabolic networks using power-laws and S-systems. Essays Biochem 2008; 45: 29-40.
95. Morley M, Molony CM, Weber TM, et al. Genetic analysis of genome-wide variation in human gene expression. Nature 2004; 430: 743-7.
96. Morahan G, Williams R. Systems genetics: the next generation in genetics research? Novartis Found Symp 2007; 281: 181-8.
97. Peirce JL, Lu L, Gu J, et al. A new set of BXD recombinant inbred lines from advanced intercross populations in mice. BMC Genet 2004; 5: 7.
98. Mountz JD, Van Zant GE, Zhang HG, et al. Genetic dissection of age-related changes of immune function in mice. Scand J Immunol 2001; 54: 10-20.
99. Damerval C, Maurice A, Josse J, et al. Quantitative trait loci underlying gene product variation, a novel perspective for analyzing regulation of genome expression. Genetics 1994; 137: 289-301.
100. Abdeltawab NF, Aziz RK, Kansal R, et al. An unbiased systems genetics approach to mapping genetic loci modulating susceptibility to severe streptococcal sepsis. PLoS Pathog 2008; 4: e1000042.
101. Aziz RK, Kotb M. Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg Infect Dis 2008; 14: 1511-7.
102. Kalia A, Spratt BG, Enright MC, et al. Influence of recombination and niche separation on the population genetic structure of the pathogen Streptococcus pyogenes. Infect Immun 2002; 70: 1971-83.
103. Kalia A, Bessen DE. Natural selection and evolution of streptococcal virulence genes involved in tissue-specific adaptations. J Bacteriol 2004; 186: 110-21.
104. Mitchell TJ. The pathogenesis of streptococcal infections: from tooth decay to meningitis. Nat Rev Microbiol 2003; 1: 219-30.
105. Basma H, Norrby-Teglund A, Guedez Y, et al. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect Immun 1999; 67: 1871-7.
106. Norrby SR, Norrby-Teglund A. Infections due to group A streptococcus: new concepts and potential treatment strategies. Ann Acad Med Singapore 1997; 26: 691-3.
107. Norrby-Teglund A, Kotb M. Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections. J Med Microbiol 2000; 49: 849-52.
108. Norrby-Teglund A, Norrby SR, Low DE. The treatment of severe Group A Streptococcal infections. Curr Infect Dis Rep 2003; 5: 28-37.
109. Low DE, Schwartz B, McGeer A. The reemergence of severe group A streptococcal disease: an evolutionary perspective. Washington, D.C: American Society for Microbiology Press 1997.
110. Chatellier S, Ihendyane N, Kansal RG, et al. Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect Immun 2000; 68: 3523-34.
111. Guidelines for the Treatment of Necrotizing Fasciitis (NF) and Streptococcal Toxic Shock Syndrome (STSS). [Accessed April 23, 2010]. Available from: http://microbiology.mtsinai.on.ca/protocols/ pdf/k5a.pdf.
112. Buchanan JT, Simpson AJ, Aziz RK, et al. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr Biol 2006; 16: 396-400.
113. Walker MJ, Hollands A, Sanderson-Smith ML, et al. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 2007; 13: 981-5.
114. Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol 2007; 120: 13-22.
115. Aziz RK, Pabst MJ, Jeng A, et al. Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB. Mol Microbiol 2004; 51: 123-34.
116. Kotb M. Bacterial exotoxins as superantigens. Clin Microbiol Rev 1995; 8: 411-26.
117. Kotb M. Superantigens of gram-positive bacteria: structurefunction analyses and their implications for biological activity. Curr Opin Microbiol 1998; 1: 56-65.
118. Kansal RG, Aziz RK, Kotb M. Modulation of expression of superantigens by human transferrin and lactoferrin: a novel mechanism in host-Streptococcus interactions. J Infect Dis 2005; 191: 2121-9.
119. Kansal RG, McGeer A, Low DE, et al. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. Infect Immun 2000; 68: 6362-9.
120. Kansal RG, Nizet V, Jeng A, et al. Selective modulation of superantigen-induced responses by streptococcal cysteine protease. J Infect Dis 2003; 187: 398-407.
121. Aziz RK, Ismail SA, Park HW, et al. Post-proteomic identification of a novel phage-encoded streptodornase, Sda1, in invasive M1T1 Streptococcus pyogenes. Mol Microbiol 2004; 54: 184-97.
122. Daneman N, McGeer A, Low DE, et al. Hospital-acquired invasive group a streptococcal infections in Ontario, Canada, 1992-2000. Clin Infect Dis 2005; 41: 334-42.
123. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996; 335: 547-54.
124. Demers B, Simor AE, Vellend H, et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993; 16: 792-800.
125. Haywood C, McGeer A, Low DE. Clinical Experience with 20 Cases of Group A Streptococcus Necrotizing Fasciitis and Myonecrosis: 1995 to 1997. Plastic Reconstructive Surgery 1999; 103: 1567-73.
126. Sharkawy A, Low DE, Saginur R, et al. Severe group a streptococcal soft-tissue infections in Ontario: 1992-1996. Clin Infect Dis 2002; 34: 454-60.
127. Weinstein M, Low D, McGeer A, et al. Invasive infection due to Streptococcus iniae: a new or previously unrecognized disease-Ontario, 1995-1996. Can Commun Dis Rep 1996; 22: 129-31.
128. Efstratiou A. Group A streptococci in the 1990s. J Antimicrob Chemother 2000; 45(Suppl): S3-12.
129. Eriksson BK, Andersson J, Holm SE, et al. Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis 1998; 27: 1428-36.
130. Eriksson BK, Andersson J, Holm SE, et al. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis 1999; 180: 410-8.
131. Hsueh PR, Wu JJ, Tsai PJ, et al. Invasive group A streptococcal disease in Taiwan is not associated with the presence of streptococcal pyrogenic exotoxin genes. Clin Infect Dis 1998; 26: 584-9.
132. Kaul R, McGeer A, Low DE, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 1997; 103: 18-24.
133. O'Brien KL, Beall B, Barrett NL, et al. Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis 2002; 35: 268-76.
134. Swanston WH, Woo J, Murphy A, et al. Invasive group A streptococcal infections. Serotype newly associated with toxic shock-like syndrome in Trinidad. Adv Exp Med Biol 1997; 418: 71-3.
135. Vlaminckx B, van Pelt W, Schouls L, et al. Epidemiological features of invasive and noninvasive group A streptococcal disease in the Netherlands, 1992-1996. Eur J Clin Microbiol Infect Dis 2004; 23: 434-44.
136. Tsiotou AG, Sakorafas GH. Management of septic shock: current concepts, with a particular emphasis on the role of source control, and future perspectives. Eur J Anaesthesiol 2004; 21: 337-60.
137. Kotb M. Diseases due to encapsulated bacteria. In: Genetic Susceptibility to Infectious Diseases. Kaslow RA, McNicholl J, Hill AVS, Eds. New York, NY: Oxford University Press 2008; pp. 351-371.
138. Norrby-Teglund A, Ihendyane N, Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis 2003; 35: 683-9.
139. Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003; 16: 379-414.
140. Trowsdale J. HLA genomics in the third millennium. Curr Opin Immunol 2005; 17: 498-504.
141. Carrington M, Martin MP. The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol 2006; 298: 225-57.
142. Dean M, Carrington M, O'Brien SJ. Balanced polymorphism selected by genetic versus infectious human disease. Annu Rev Genomics Hum Genet 2002; 3: 263-92.
143. Hill AV. HLA and infection. J R Coll Phys Lond 1992; 26: 11-6.
144. Kaslow RA, Shaw S. The role of histocompatibility antigens (HLA) in infection. Epidemiol Rev 1981; 3: 90-114.
145. Nepom GT. MHC genes in HLA-associated disease. Curr Opin Immunol 1989; 2: 588-92.
146. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54: 535-51.
147. Charron D. HLA class II disease associations: Molecular basis. J Autoimmun 1992; 5: 45-53.
148. Nooh MM, El-Gengehi N, Kansal R, et al. HLA transgenic mice provide evidence for a direct and dominant role of HLA class II variation in modulating the severity of streptococcal sepsis. J Immunol 2007; 178: 3076-83.
149. Norrby-Teglund A, Chatellier S, Low DE, et al. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur J Immunol 2000; 30: 3247-55.
150. Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases. Clin Microbiol Rev 2009; 22: 370-85.
151. Fraser J, Arcus V, Kong P, et al. Superantigens powerful modifiers of the immune system. Mol Med Today 2000; 6: 125-32.
152. Proft T, Fraser JD. Streptococcal superantigens. Chem Immunol Allergy 2007; 93: 1-23.
153. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13: 470-511.
154. Kreikemeyer B, McIver KS, Podbielski A. Virulence factor regulation and regulatory networks in Streptococcus pyogenes and their impact on pathogen-host interactions. Trends Microbiol 2003; 11: 224-32.
155. Ayroles JF, Carbone MA, Stone EA, et al. Systems genetics of complex traits in Drosophila melanogaster. Nat Genet 2009; 41: 299-307.
156. Chesler EJ, Miller DR, Branstetter LR, et al. The Collaborative Cross at Oak Ridge National Laboratory: developing a powerful resource for systems genetics. Mamm Genome 2008; 19: 382-9.
157. Iraqi FA, Churchill G, Mott R. The Collaborative Cross, developing a resource for mammalian systems genetics: a status report of the Wellcome Trust cohort. Mamm Genome 2008; 19: 379-81.
158. Zhu M, Yu M, Zhao S. Understanding quantitative genetics in the systems biology era. Int J Biol Sci 2009; 5: 161-70.
159. Williams RB, Chan EK, Cowley MJ, et al. The influence of genetic variation on gene expression. Genome Res 2007; 17: 1707-16.
160. Williams RW. A targeted screen to detect recessive mutations that have quantitative effects. Mamm Genome 1999; 10: 734-8.
161. Alper S, Laws R, Lackford B, et al. Identification of innate immunity genes and pathways using a comparative genomics approach. Proc Natl Acad Sci USA 2008; 105: 7016-21.
162. Sakata T, Winzeler EA. Genomics, systems biology and drug development for infectious diseases. Mol Biosyst 2007; 3: 841-8.
163. Boshoff HI, Manjunatha UH. The impact of genomics on discovering drugs against infectious diseases. Microbes Infect 2006; 8: 1654-61.
164. Polpitiya AD, McDunn JE, Burykin A, et al. Using systems biology to simplify complex disease: immune cartography. Crit Care Med 2009; 37: S16-21.
165. Kay E, Wren BW. Recent advances in systems microbiology. Curr Opin Microbiol 2009; 12: 577-81.
166. Sturzl M, Konrad A, Alkharsah KR, et al. The contribution of systems biology and reverse genetics to the understanding of Kaposi's sarcoma-associated herpesvirus pathogenesis in endothelial cells. Thromb Haemost 2009; 102: 1117-34.
167. Uetz P, Rajagopala SV, Dong YA, et al. From ORFeomes to protein interaction maps in viruses. Genome Res 2004; 14: 2029-33.
168. Mani K. Systems biology and personalized medicine in cancer. Curr Pharmacogenomics Person Med 2010; 8: 64-72.
169. Pang T. Germs, genomics and global public health. How can advances in genomic sciences be integrated into public health in the developing world to deal with infectious diseases? HUGO J 2009; 3: 5-9.